Cerus (CERS) Stock Price, News & Analysis

Company Overview

Cerus Corporation is a biomedical products company focused on improving the safety of blood transfusions. The company develops and commercializes technologies designed to reduce the risk of transfusion-transmitted infections by inactivating certain viruses, bacteria, parasites and white blood cells in donated blood components.

Its principal product platform is the INTERCEPT Blood System, which uses amotosalen and ultraviolet A light to treat blood components. The system is used with platelet and plasma components, and Cerus has also developed applications for red blood cells and cryoprecipitation. Product availability and regulatory clearances vary by geography and blood component.

Founded in 1991 and headquartered in Concord, California, Cerus serves blood centers, hospitals and other healthcare organizations in the United States and international markets. Its products have received regulatory authorizations in the United States, Europe and other countries. William M. “Bill” Greenman has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $2.45 to $2.51
• 50-Day Range: $2.15 to $3.28
• 52-Week Range: $1.20 to $3.47
• Volume: 1.54 million shs
• Average Volume: 1.41 million shs
• Market Capitalization: $501.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.25
• Consensus Rating: Hold

Cerus Stock Analysis - MarketRank™

Cerus scored higher than 39% of companies evaluated by MarketBeat, and ranked 677th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Cerus has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Cerus has a consensus price target of $5.25, representing about 110.8% upside from its current price of $2.49.

Amount of Analyst Coverage

Cerus has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cerus is -83.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cerus is -83.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cerus has a P/B Ratio of 7.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.28% of the float of Cerus has been sold short.

Short Interest Ratio / Days to Cover

Cerus has a short interest ratio ("days to cover") of 10.02, which indicates bearish sentiment.

Change versus previous month

Short interest in Cerus has recently increased by 2.23%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cerus does not currently pay a dividend.

Dividend Growth

Cerus does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.77

News Sentiment

Cerus has a news sentiment score of 1.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cerus this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for CERS on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

3 people have added Cerus to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $684,112.00 in company stock.

Percentage Held by Insiders

5.30% of the stock of Cerus is held by insiders.

Percentage Held by Institutions

78.37% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 9/13/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:CERS
• CIK: 1020214
• Web: www.cerus.com
• Phone: (925) 288-6000
• Fax: 925-288-6001
• Employees: 345
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Cerus: $5.25
• High Price Target: $6.50
• Low Price Target: $4.00
• Potential Upside/Downside: +110.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.63 million
• Net Margins: -3.06%
• Pretax Margin: -2.91%
• Return on Equity: -10.19%
• Return on Assets: -3.14%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 1.83
• Quick Ratio: 1.07

Sales & Book Value

• Annual Sales: $206.13 million
• Price / Sales: 2.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.34 per share
• Price / Book: 7.32

Miscellaneous

• Outstanding Shares: 201,520,000
• Free Float: 190,844,000
• Market Cap: $501.78 million
• Optionable: Optionable
• Beta: 1.80